Li Ma, PhD

Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor 
Research Institute, Beijing, China

Dr. Li Ma got her B.S. in Clinical Medicine from Shanxi Medical University, M.S. in Human Anatomy and Histology Embryology from the Forth Military Medical University, and Ph.D. in Oncology from Chinese Academy of Medical Sciences & Peking Union Medical College. Her Ph.D. dissertation focused on the detection of cancer biomarkers and clinical evaluation of precision cancer medicine. Right now she is an oncologist in Beijing Chest Hospital. As a doctor, she has focused on both basic researches for novel biomarkers and clinical outcome of targeted medicine. At the university, she is collaborating with faculty members on developing molecular biomarkers detection guidelines with variable methods, evaluating the clinical significance of the assays, and explored the molecular signal regulation mechanisms of the new biomarkers. The key interest is developing therapeutic strategies that overcome resistance to ALK inhibitors. Also, she is responsible for collecting the clinical data and participating in randomized control trials to analyze the outcome and effect of the targeted medicine.  She has many publications in the field of breast carcinoma and lung carcinoma, especially in the clinical evaluation and biomarkers detection of ALK tyrosine kinase inhibitors, EGFR tyrosine kinase inhibitors in lung malignancies and anti-HER2 therapy in breast malignances.